PDF herunterladen
Int J Angiol 2020; 29(01): 002-011
DOI: 10.1055/s-0040-1701639
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?

Akshyaya Pradhan 
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Monika Bhandari
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Pravesh Vishwakarma
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
,
Rishi Sethi
1   Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Februar 2020 (online)

    Lizenzen und Reprints

Abstract

The causal linkage between triglycerides and coronary artery disease has been controversial. Most of the trials hitherto have shown marginal or no beneficial effects of reduction of triglycerides (with fibrates) on top of low-density lipoprotein (LDL) reduction. But a significant residual cardiovascular risk remains even after use of high dose of statins. Omega-3 fatty acids have been shown to reduce triglyceride levels and some old trials have shown the benefits of fish oils in reducing cardiovascular events. However, barring a few trials most of the large trials of omega-3 fatty acids are negative. Recently, few large trials have been conducted to see the effects of high dose omega-3 fatty acids on cardiovascular outcomes and some of them have shown promising results on top of LDL reduction.

Keywords

triglycerides - cardiovascular disease - omega-3 fatty acids - statins
 

  • References

  • 1 Jacobs Jr DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982; 116 (06) 878-885
    CrossrefPubMedGoogle Scholar
  • 2 Criqui MH, Heiss G, Cohn R. , et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328 (17) 1220-1225
    CrossrefPubMedGoogle Scholar
  • 3 Grundy SM, Stone NJ, Bailey AL. , et al. AHA/ACC /AACVPR/AAPA/ ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 (24) 3168-3209
    CrossrefPubMedGoogle Scholar
  • 4 Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60 (03) 473-485
    CrossrefPubMedGoogle Scholar
  • 5 Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980; 302 (25) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 6 Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?. Clin Chem 2008; 54 (01) 11-13
    CrossrefPubMedGoogle Scholar
  • 7 Fontbonne A, Eschwège E, Cambien F. , et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32 (05) 300-304
    CrossrefPubMedGoogle Scholar
  • 8 Tirosh A, Rudich A, Shochat T. , et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007; 147 (06) 377-385
    PubMedGoogle Scholar
  • 9 Sarwar N, Danesh J, Eiriksdottir G. , et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115 (04) 450-458
    CrossrefPubMedGoogle Scholar
  • 10 Patel S, Puranik R, Nakhla S. , et al. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009; 204 (02) 424-428
    CrossrefPubMedGoogle Scholar
  • 11 Di Angelantonio E, Sarwar N, Perry P. , et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302 (18) 1993-2000
    CrossrefPubMedGoogle Scholar
  • 12 Di Angelantonio E, Sarwar N, Perry P. , et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302 (18) 1993-2000
    CrossrefPubMedGoogle Scholar
  • 13 Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61 (04) 427-436
    CrossrefPubMedGoogle Scholar
  • 14 Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34 (24) 1826-1833
    CrossrefPubMedGoogle Scholar
  • 15 Sarwar N, Sandhu MS, Ricketts SL. , et al; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375 (9726): 1634-1639
    CrossrefPubMedGoogle Scholar
  • 16 Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem 2014; 60 (05) 737-746
    CrossrefPubMedGoogle Scholar
  • 17 Baigent C, Keech A, Kearney PM. , et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-1278
    CrossrefPubMedGoogle Scholar
  • 18 Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48 (03) 438-445
    CrossrefPubMedGoogle Scholar
  • 19 Kearney PM, Blackwell L, Collins R. , et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371 (9607): 117-125
    CrossrefPubMedGoogle Scholar
  • 20 Baigent C, Blackwell L, Emberson J. , et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376 (9753): 1670-1681
    CrossrefPubMedGoogle Scholar
  • 21 Mihaylova B, Emberson J, Blackwell L. , et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380 (9841): 581-590
    CrossrefPubMedGoogle Scholar
  • 22 Fulcher J, O'Connell R, Voysey M. , et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385 (9976): 1397-1405
    CrossrefPubMedGoogle Scholar
  • 23 Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20 (04) 614-620
    CrossrefPubMedGoogle Scholar
  • 24 Girman CJ, Rhodes T, Mercuri M. , et al; 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93 (02) 136-141
    CrossrefPubMedGoogle Scholar
  • 25 Sacks FM, Alaupovic P, Moye LA. , et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102 (16) 1886-1892
    CrossrefPubMedGoogle Scholar
  • 26 Sattar N, Gaw A, Scherbakova O. , et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108 (04) 414-419
    CrossrefPubMedGoogle Scholar
  • 27 Deedwania P, Barter P, Carmena R. , et al; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368 (9539): 919-928
    CrossrefPubMedGoogle Scholar
  • 28 Pfeffer MA, Sacks FM, Moyé LA. , et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and recurrent events. J Am Coll Cardiol 1999; 33 (01) 125-130
    CrossrefPubMedGoogle Scholar
  • 29 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19) 1349-1357
    CrossrefPubMedGoogle Scholar
  • 30 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
    CrossrefPubMedGoogle Scholar
  • 31 Shepherd J, Cobbe SM, Ford I. , et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20) 1301-1307
    CrossrefPubMedGoogle Scholar
  • 32 Manninen V, Tenkanen L, Koskinen P. , et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 33 Rubins HB, Robins SJ, Collins D. , et al; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341 (06) 410-418
    CrossrefPubMedGoogle Scholar
  • 34 Jun M, Foote C, Lv J. , et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375 (9729): 1875-1884
    CrossrefPubMedGoogle Scholar
  • 35 Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010; 363 (07) 692-694 , author reply 694–695
    CrossrefPubMedGoogle Scholar
  • 36 Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 57 (02) 267-272
    CrossrefPubMedGoogle Scholar
  • 37 Cannon CP, Blazing MA, Giugliano RP. , et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372 (25) 2387-2397
    CrossrefPubMedGoogle Scholar
  • 38 Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011; 58 (20) 2047-2067
    CrossrefPubMedGoogle Scholar
  • 39 Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975; 28 (09) 958-966
    CrossrefPubMedGoogle Scholar
  • 40 Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312 (19) 1205-1209
    CrossrefPubMedGoogle Scholar
  • 41 Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012; 15 (04) 725-737
    CrossrefPubMedGoogle Scholar
  • 42 Burr ML, Fehily AM, Gilbert JF. , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2 (8666): 757-761
    PubMedGoogle Scholar
  • 43 Burr ML, Ashfield-Watt PA, Dunstan FD. , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57 (02) 193-200
    CrossrefPubMedGoogle Scholar
  • 44 Aung T, Halsey J, Kromhout D. , et al; Omega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77−917 individuals. JAMA Cardiol 2018; 3 (03) 225-234
    CrossrefPubMedGoogle Scholar
  • 45 Roncaglioni MC, Tombesi M, Avanzini F. , et al; Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. [published correction appears in N Engl J Med. 2013;368:2146] N Engl J Med 2013; 368 (19) 1800-1808
    CrossrefPubMedGoogle Scholar
  • 46 Bonds DE, Harrington M, Worrall BB. , et al; Writing Group for the AREDS2 Research Group. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014; 174 (05) 763-771
    CrossrefPubMedGoogle Scholar
  • 47 Bowman L, Mafham M, Stevens W. , et al; ASCEND Study Collaborative Group. ASCEND: a study of cardiovascular events in diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J 2018; 198: 135-144
    CrossrefPubMedGoogle Scholar
  • 48 Manson JE, Bassuk SS, Lee IM. , et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012; 33 (01) 159-171
    CrossrefPubMedGoogle Scholar
  • 49 National Library of Medicine Outcomes study to assess STatin Residual risk reduction with EpaNova in hiGh CV risk patienTs with Hypertriglyceridemia (STRENGTH), 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT02104817 . Accessed December 15, 2017
    PubMed
  • 50 Bhatt DL, Steg PG, Miller M. , et al; REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol 2019; 73 (22) 2791-2802
    PubMedGoogle Scholar
  • 51 Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88 (4 Pt 1): 1421-1430
    CrossrefPubMedGoogle Scholar
  • 52 GISSI-Prevenzione Investigators (GruppoItalianoperlo Studiodella Sopravvivenzanell' Infartomiocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354 (9177): 447-455
    CrossrefPubMedGoogle Scholar
  • 53 Yokoyama M, Origasa H, Matsuzaki M. , et al; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369 (9567): 1090-1098
    CrossrefPubMedGoogle Scholar
  • 54 Tavazzi L, Maggioni AP, Marchioli R. , et al; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9645): 1223-1230
    CrossrefPubMedGoogle Scholar
  • 55 Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. ; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010; 341: c6273
    CrossrefPubMedGoogle Scholar
  • 56 Kromhout D, Giltay EJ, Geleijnse JM. ; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363 (21) 2015-2026
    CrossrefPubMedGoogle Scholar
  • 57 Rauch B, Schiele R, Schneider S. , et al; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122 (21) 2152-2159
    CrossrefPubMedGoogle Scholar
  • 58 Bosch J, Gerstein HC, Dagenais GR. , et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367 (04) 309-318
    CrossrefPubMedGoogle Scholar
  • 59 Arnett DK, Blumenthal RS, Albert MA. , et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Circulation 2019; 140 (11) e596-e646
    PubMedGoogle Scholar
  • 60 Grundy SM, Stone NJ, Bailey AL. , et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 (24) e285-e350
    CrossrefPubMedGoogle Scholar